Pfizer licenses Novavax's Matrix-M adjuvant for $530M potential value, signaling a vaccine strategy pivot two months after divesting BioNTech stake.

Pfizer Licenses Novavax's Matrix-M Adjuvant for Up to $530M

Pfizer CEO compares obesity drug market to Viagra, plans 10 Phase 3 trials in 2026 after $10B Metsera acquisition. What it means for the $150B market.

Pfizer Goes 'All In' on Obesity With 10 Phase 3 Trials Planned After $10B Metsera Bet

350 Drug Price Hikes Set for January Despite Trump's 'Historic' Pharma Deals

Patient Death in Hympavzi Trial Deepens Pfizer's Blood Disorder Woes

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Q2 2024

PFIZER (PFE) Earnings Call Transcripts